EUCTR2005-005680-29-IT进行中（未招募）不适用
VINORELBINE AND CAPECITABINE as first line treatment in advanced breast cancer patients with non measurable lesions for RECIST criteria - VNBCAP
AZIENDA OSPEDALIERA S. LUIGI GONZAGA0 个研究点目标入组 100 人开始时间: 2007年2月22日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •metastatic breast carcinoma non measurable lesions for RECIST criteria progression after loco-regional therapy
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •previous first line chemotherapy previous second and third line hormonotherapy for advanced disease diagnosis of advanced disease with only elevated markers
研究者
相似试验
进行中（未招募）
不适用
Capecitabine and bevacizumab ± vinorelbine as 1st line treatment in HER2/neu-negative metastatic or locally advanced inoperable breast cancer patientsEUCTR2008-003779-37-DEiOMEDICO AG
进行中（未招募）
不适用
Adjunction with Capecitabin, Lapatinib and Vinorelbin to treat patients with HER2/new-positive, advanced or metastized breast cancer after failure of TrastuzumabFemale patients with HER2/new-positive, locally advanced or metastized breast cancer after failure of chemotherapy with TrastuzumabMedDRA version: 15.0Level: PTClassification code 10006187Term: Breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2009-017219-13-DEDeutsche Krebsgesellschaft Sponsor GmbH
进行中（未招募）
不适用
VINORELBINE, CARBOPLATIN AND TRASTUZUMAB IN ADVANCED HER-2 POSITIVE BREAST CANCER. A PHASE 2 STUDY - VinCaTBREAST CANCEREUCTR2006-003994-28-ITISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI - FONDAZIONE G. PASCALE
进行中（未招募）
1 期
Second line ERIbulin followed by CApecitabine or the reverse sequence in HER2-negative Metastatic Breast Cancer (MBC) patients: a randomized phase II study – ERICA trialEUCTR2017-004652-35-ITCONSORZIO ONCOTECH150
进行中（未招募）
1 期
ORAL VINORELBINE AND CISPLATIN WITH CONCOMITANT RADIOTHERAPY FOLLOWED BY EITHER CONSOLIDATION THERAPY WITH ORAL VINORELBINE AND CISPLATIN PLUS BEST SUPPORTIVE CARE OR BEST SUPPORTIVE CARE ALONE IN STAGE III NON SMALL CELL LUNG CANCER (NSCLC): A RANDOMIZED PHASE III STUDYEUCTR2004-005135-26-DEPierre Fabre Médicament376